A word on injectable peptides A huge and largely unregulated market has emerged around injectable peptides, with most bought directly online - think longevity compounds, tanning agents, and recovery aids
And a small clinical trial in people with Alzheimers disease uncovered signs of slowed cognitive decline in those treated with the first generation GLP-1 drug liraglutide, Edisons team reports December 1 in Nature Medicine
10.1016/j.brs.2019.12.016 81
Licensing (Marketing Authorisation): The MHRA has approved: Semaglutide (Wegovy) for adults with BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbidity Liraglutide (Saxenda) with similar BMI criteria NHS Access (NICE Guidance): According to NICE guidance (TA664 for semaglutide), NHS-funded treatment is more restricted and typically available for adults with: BMI 35 kg/m with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) For individuals from Black, Asian, and minority ethnic backgrounds, lower BMI thresholds may apply, recognising that these populations face increased metabolic risk at lower BMI levels
